First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

被引：23
|
作者：
Baselga, J.
Bradbury, I.
Eidtmann, H.
Di Cosimo, S.
Aura, C.
De Azambuja, E.
Gomez, H.
Dinh, P.
Fauria, K.
Van Dooren, V.
Paoletti, P.
Goldhirsch, A.
Chang, T-W
Lang, I.
Untch, M.
Gelber, R. D.
Piccart-Gebhart, M.
机构：
[1] Vall dHebron Univ Hosp, NeoALTTO Study Team, Barcelona, Spain
[2] FSS Ltd, Kincraig, Scotland
[3] Univ Hosp Kiel, Kiel, Germany
[4] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain
[5] SOLTI Spanish Breast Canc Res Grp, Barcelona, Spain
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] Breast European Adjuvant Study Team, Brussels, Belgium
[8] Inst Nacl Enfermedades Neoplas, Lima, Peru
[9] Breast Int Grp, Brussels, Belgium
[10] GlaxoSmithKline, Collegeville, PA USA
[11] European Inst Oncol, Milan, Italy
[12] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[13] Natl Inst Oncol, Budapest, Hungary
[14] Charite, Acad Hosp, D-13353 Berlin, Germany
[15] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-S3-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-3
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Baselga, Jose
    Bradbury, Ian
    Eidtmann, Holger
    Di Cosimo, Serena
    de Azambuja, Evandro
    Aura, Claudia
    Gomez, Henry
    Dinh, Phuong
    Fauria, Karine
    Van Dooren, Veerle
    Aktan, Gursel
    Goldhirsch, Aron
    Chang, Tsai-Wang
    Horvath, Zsolt
    Coccia-Portugal, Maria
    Domont, Julien
    Tseng, Ling-Min
    Kunz, Georg
    Sohn, Joo Hyuk
    Semiglazov, Vladimir
    Lerzo, Guillermo
    Palacova, Marketa
    Probachai, Volodymyr
    Pusztai, Lajos
    Untch, Michael
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    LANCET, 2012, 379 (9816): : 633 - 640
  • [2] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [3] Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
    Huober, Jens
    Holmes, Eileen
    Baselga, Jose
    de Azambuja, Evandro
    Untch, Michael
    Fumagalli, Debora
    Sarp, Severine
    Lang, Istvan
    Smith, Ian
    Boyle, Frances
    Xu, Binghe
    Lecocq, Christophe
    Wildiers, Hans
    Jouannaud, Christelle
    Hackman, John
    Dasappa, Lokanatha
    Ciruelos, Eva
    Toral Pena, Juan Carlos
    Adamchuk, Hryhoriy
    Hickish, Tamas
    de la Pena, Lorena
    Jackisch, Christian
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    Di Cosimo, Serena
    EUROPEAN JOURNAL OF CANCER, 2019, 118 : 169 - 177
  • [4] Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.
    Carey, Lisa A.
    Berry, Donald A.
    Ollila, David
    Harris, Lyndsay
    Krop, Ian E.
    Weckstein, Douglas
    Henry, Norah Lynn
    Anders, Carey K.
    Cirrincione, Constance
    Winer, Eric P.
    Perou, Charles M.
    Hudis, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.
    Nuciforo, P.
    Townend, J.
    Saura, C.
    de Azumbaja, E.
    Hilbers, F.
    Manukyants, A.
    Werutsky, G.
    Bliss, J.
    Moebus, V.
    Colleoni, M.
    Aspitia, A. Moreno
    Di Cosimo, S.
    Van Dooren, V.
    Kroep, J.
    Ferro, A.
    Cameron, D.
    Gelber, R.
    Piccart-Gebhart, M.
    Huober, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S15 - S16
  • [6] Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
    Lavasani, Sayeh M.
    Somlo, George
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Daniel
    Yeon, Christina
    Yuan, Yuan
    Waisman, James R.
    Mortimer, Joanne
    CANCER, 2023, 129 (05) : 740 - 749
  • [7] A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer
    Rimawi, Mothaffar F.
    Aleixo, Sabina B.
    Alarcon Rozas, Ashley
    de Matos Neto, Joao Nunes
    Caleffi, Maira
    Figueira, Alicardo Cesar
    Souza, Sulene Cunha
    Reiriz, Andre B.
    Gutierrez, Carolina
    Arantes, Heloisa
    Uttenreuther-Fischer, Martina M.
    Solca, Flavio
    Osborne, C. Kent
    CLINICAL BREAST CANCER, 2015, 15 (02) : 101 - 109
  • [8] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Patel, Tejal A.
    Ensor, Joe E.
    Creamer, Sarah L.
    Boone, Toniva
    Rodriguez, Angel A.
    Niravath, Poly A.
    Darcourt, Jorge G.
    Meisel, Jane L.
    Li, Xiaoxian
    Zhao, Jing
    Kuhn, John G.
    Rosato, Roberto R.
    Qian, Wei
    Belcheva, Anna
    Schwartz, Mary R.
    Kaklamani, Virginia G.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [9] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Tejal A. Patel
    Joe E. Ensor
    Sarah L. Creamer
    Toniva Boone
    Angel A. Rodriguez
    Poly A. Niravath
    Jorge G. Darcourt
    Jane L. Meisel
    Xiaoxian Li
    Jing Zhao
    John G. Kuhn
    Roberto R. Rosato
    Wei Qian
    Anna Belcheva
    Mary R. Schwartz
    Virginia G. Kaklamani
    Jenny C. Chang
    Breast Cancer Research, 21
  • [10] A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer.
    Crown, J. P.
    Moulton, B.
    O'Donovan, N.
    CANCER RESEARCH, 2012, 72
12345